Literature DB >> 27185370

Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.

Rekha Gyanchandani1, Yan Lin2, Hui-Min Lin2, Kristine Cooper2, Daniel P Normolle2, Adam Brufsky3, Michael Fastuca1, Whitney Crosson1, Steffi Oesterreich1, Nancy E Davidson3, Rohit Bhargava4, David J Dabbs4, Adrian V Lee5.   

Abstract

PURPOSE: To examine the effect of intratumor heterogeneity (ITH) on detection of genes within gene expression panels (GEPs) and the subsequent ability to predict prognostic risk. EXPERIMENTAL
DESIGN: Multiplexed barcoded RNA analysis was used to measure the expression of 141 genes from five GEPs (Oncotype Dx, MammaPrint, PAM50, EndoPredict, and Breast Cancer Index) in breast cancer tissue sections and tumor-rich cores from 71 estrogen receptor (ER)-positive node-negative tumors, on which clinical Oncotype Dx testing was previously performed. If the tumor had foci of high Ki67 (n = 26), low/negative progesterone receptor (PR; n = 13), or both (n = 5), additional cores were obtained. In total, 181 samples were processed. Oncotype Dx recurrence scores were calculated from NanoString nCounter gene expression data.
RESULTS: Hierarchical clustering using all GEP genes showed that majority (61 of 71) of tumor samples clustered by patient, indicating greater interpatient heterogeneity (IPH) than ITH. We found a strikingly high correlation between Oncotype Dx recurrence scores obtained from whole sections versus tumor-rich cores (r = 0.94). However, high Ki67 and low PR cores had slightly higher but not statistically significant recurrence scores. For 18 of 71 (25%) patients, scores were divergent between sections and cores and crossed the boundaries for low, intermediate, and high risk.
CONCLUSIONS: Our study indicates that in patients with highly heterogeneous tumors, GEP recurrence scores from a single core could under- or overestimate prognostic risk. Hence, it may be a useful strategy to assess multiple samples (both representative and atypical cores) to fully account for the ITH-driven variation in risk prediction. Clin Cancer Res; 22(21); 5362-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27185370      PMCID: PMC5093028          DOI: 10.1158/1078-0432.CCR-15-2889

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

2.  A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Authors:  Martin Filipits; Margaretha Rudas; Raimund Jakesz; Peter Dubsky; Florian Fitzal; Christian F Singer; Otto Dietze; Richard Greil; Andrea Jelen; Paul Sevelda; Christa Freibauer; Volkmar Müller; Fritz Jänicke; Marcus Schmidt; Heinz Kölbl; Achim Rody; Manfred Kaufmann; Werner Schroth; Hiltrud Brauch; Matthias Schwab; Peter Fritz; Karsten E Weber; Inke S Feder; Guido Hennig; Ralf Kronenwett; Mathias Gehrmann; Michael Gnant
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Quantitative analysis of estrogen receptor heterogeneity in breast cancer.

Authors:  Gina G Chung; Maciej P Zerkowski; Sriparna Ghosh; Robert L Camp; David L Rimm
Journal:  Lab Invest       Date:  2007-03-05       Impact factor: 5.662

5.  Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems.

Authors:  Louis P. Pertschuk; Constantine A. Axiotis; Joseph G. Feldman; Yong-Doo Kim; Sebastian J. Karavattayhayyil; Lorraine Braithwaite
Journal:  Breast J       Date:  1999-11       Impact factor: 2.431

6.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

Authors:  Nicholas J Szerlip; Alicia Pedraza; Debyani Chakravarty; Mohammad Azim; Jeremy McGuire; Yuqiang Fang; Tatsuya Ozawa; Eric C Holland; Jason T Huse; Suresh Jhanwar; Margaret A Leversha; Tom Mikkelsen; Cameron W Brennan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

7.  Genomic subtypes in choosing adjuvant therapy for breast cancer.

Authors:  Amelia B Zelnak; Ruth M O'Regan
Journal:  Oncology (Williston Park)       Date:  2013-03       Impact factor: 2.990

8.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Authors:  Sakshi Gulati; Pierre Martinez; Tejal Joshi; Nicolai Juul Birkbak; Claudio R Santos; Andrew J Rowan; Lisa Pickering; Martin Gore; James Larkin; Zoltan Szallasi; Paul A Bates; Charles Swanton; Marco Gerlinger
Journal:  Eur Urol       Date:  2014-07-19       Impact factor: 20.096

Review 10.  Multigene prognostic tests in breast cancer: past, present, future.

Authors:  Balázs Győrffy; Christos Hatzis; Tara Sanft; Erin Hofstatter; Bilge Aktas; Lajos Pusztai
Journal:  Breast Cancer Res       Date:  2015-01-27       Impact factor: 6.466

View more
  20 in total

1.  Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Authors:  Lan Cao; Ahmed Basudan; Matthew J Sikora; Amir Bahreini; Nilgun Tasdemir; Kevin M Levine; Rachel C Jankowitz; Priscilla F McAuliffe; David Dabbs; Sue Haupt; Ygal Haupt; Peter C Lucas; Adrian V Lee; Steffi Oesterreich; Jennifer M Atkinson
Journal:  Cancer Lett       Date:  2019-06-20       Impact factor: 8.679

2.  Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?

Authors:  Brenda F Kurland; Steffi Oesterreich
Journal:  J Nucl Med       Date:  2018-06-14       Impact factor: 10.057

3.  A novel prognostic two-gene signature for triple negative breast cancer.

Authors:  Mansour A Alsaleem; Graham Ball; Michael S Toss; Sara Raafat; Mohammed Aleskandarany; Chitra Joseph; Angela Ogden; Shristi Bhattarai; Padmashree C G Rida; Francesca Khani; Melissa Davis; Olivier Elemento; Ritu Aneja; Ian O Ellis; Andrew Green; Nigel P Mongan; Emad Rakha
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

4.  A clonal expression biomarker associates with lung cancer mortality.

Authors:  Dhruva Biswas; Nicolai J Birkbak; Rachel Rosenthal; Crispin T Hiley; Emilia L Lim; Krisztian Papp; Stefan Boeing; Marcin Krzystanek; Dijana Djureinovic; Linnea La Fleur; Maria Greco; Balázs Döme; János Fillinger; Hans Brunnström; Yin Wu; David A Moore; Marcin Skrzypski; Christopher Abbosh; Kevin Litchfield; Maise Al Bakir; Thomas B K Watkins; Selvaraju Veeriah; Gareth A Wilson; Mariam Jamal-Hanjani; Judit Moldvay; Johan Botling; Arul M Chinnaiyan; Patrick Micke; Allan Hackshaw; Jiri Bartek; Istvan Csabai; Zoltan Szallasi; Javier Herrero; Nicholas McGranahan; Charles Swanton
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

Review 5.  Tracking Cancer Evolution through the Disease Course.

Authors:  Chris Bailey; James R M Black; James L Reading; Kevin Litchfield; Samra Turajlic; Nicholas McGranahan; Mariam Jamal-Hanjani; Charles Swanton
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 38.272

6.  MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Authors:  Irene Romero; Cristina Garrido; Ignacio Algarra; Virginia Chamorro; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

7.  Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip.

Authors:  Lucas Delmonico; Said Attiya; Joan W Chen; John C Obenauer; Edward C Goodwin; Marcia V Fournier
Journal:  Dis Markers       Date:  2019-05-14       Impact factor: 3.434

8.  DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling.

Authors:  F J Campos-Laborie; A Risueño; M Ortiz-Estévez; B Rosón-Burgo; C Droste; C Fontanillo; R Loos; J M Sánchez-Santos; M W Trotter; J De Las Rivas
Journal:  Bioinformatics       Date:  2019-10-01       Impact factor: 6.937

9.  Comprehensive Analysis of an Individualized Immune-Related lncRNA Pair Signature in Gastric Cancer.

Authors:  Chuang Nie; Jiabao Zhai; Qi Wang; Xiaojie Zhu; Guanghui Xiang; Chang Liu; Tianyu Liu; Wanyu Wang; Yimin Wang; Yashuang Zhao; Wenjing Tian; Yingwei Xue; Haibo Zhou
Journal:  Front Cell Dev Biol       Date:  2022-02-22

10.  Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers.

Authors:  Daniel M Spagnolo; Rekha Gyanchandani; Yousef Al-Kofahi; Andrew M Stern; Timothy R Lezon; Albert Gough; Dan E Meyer; Fiona Ginty; Brion Sarachan; Jeffrey Fine; Adrian V Lee; D Lansing Taylor; S Chakra Chennubhotla
Journal:  J Pathol Inform       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.